-+ 0.00%
-+ 0.00%
-+ 0.00%

NKGen Biotech Reports Sustained Cognitive Improvement in Single Alzheimer's Patient Treated With Troculeucel

PUBT·11/16/2026 18:05:20
Listen to the news
NKGen Biotech Reports Sustained Cognitive Improvement in Single Alzheimer's Patient Treated With Troculeucel
  • NKGen Biotech presented long-term observations of investigational Alzheimer's therapy troculeucel in one patient at the CTAD 2026 conference.
  • The patient's condition improved from moderate to mild Alzheimer's within three months, with improvement maintained through 24 months of cumulative treatment.
  • No treatment-related adverse events were reported during either treatment period.
  • Single-patient findings cannot establish efficacy; an ongoing randomized, placebo-controlled Phase 2a trial has an interim analysis expected in the second half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611161305PRIMZONEFULLFEED9877586) on November 16, 2026, and is solely responsible for the information contained therein.